PeptiDream ends successfully preclinical trials of iHA-24, an anti-influenza peptide

Based on PeptiDreams PDPS (Peptide Discovery Platform System), the macrocyclic peptide iHA-24 was found effective in preventing both viral infection and viral proliferation in both cell-based experiments and mouse-based animal studies. iHA-24 was also found to exhibit inhibition activity equal to or even higher than that of the current neuraminidase inhibitors. Peptide iHA-24 also exhibited broad influenza strain efficacy against H1N1 (2009 pandemic strain), H5N1 (bird flu, SARS), and H2N2 strains. The drug will now enter clinical studies.

Source: PeptiDream news release, February 8, 2018

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint